Going from an open benefit to a limited-use benefit, do you have other criteria that you're applying in addition to only the clinical application of the pharmaceutical? In your DBL you said there was an open benefit, a limited-use benefit, and then there's an exception, so for the limited-use benefit, is someone applying some kind of criteria in addition to the clinical performance of the drug?
On December 1st, 2016. See this statement in context.